Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials

In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment cessation (MR(4) or deeper, corresponding to BCR-ABL1 ≤ 0.01% on the International Scale (IS)) is considered as a prognostic factor for treatment free remission in stopping trials. MR level determination...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiess, Birgit, Rinaldetti, Sébastien, Naumann, Nicole, Galuschek, Norbert, Kossak-Roth, Ute, Wuchter, Patrick, Tarnopolscaia, Irina, Rose, Diana, Voskanyan, Astghik, Fabarius, Alice, Hofmann, Wolf-Karsten, Saußele, Susanne, Seifarth, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428315/
https://www.ncbi.nlm.nih.gov/pubmed/30897165
http://dx.doi.org/10.1371/journal.pone.0214305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428315/
https://www.ncbi.nlm.nih.gov/pubmed/30897165
http://dx.doi.org/10.1371/journal.pone.0214305

Ejemplares similares